PET IMAGING IN UROLOGY: Edited by Stefano Fanti and Declan G. MurphyProstate-specific membrane antigen targeted PET imaging for prostate cancer recurrenceFerdinandus, Justina; Fendler, Wolfgang Petera; Hadaschik, Borisb; Herrmann, KenaAuthor Information aDepartment of Nuclear Medicine bDepartment of Urology, University of Duisburg-Essen and German Cancer Consortium (DKTK), University Hospital Essen, Essen, Germany Correspondence to Ken Herrmann, MD, Department of Nuclear Medicine, University of Duisburg-Essen and German Cancer Consortium (DKTK), University Hospital Essen, Hufelandstraße 55, 45147 Essen, Germany. Tel: +49 201 723 2032; e-mail: email@example.com Current Opinion in Urology: September 2020 - Volume 30 - Issue 5 - p 635-640 doi: 10.1097/MOU.0000000000000793 Buy Metrics Abstract Purpose of review Prostate-specific membrane antigen targeted PET imaging (PSMA PET) of biochemically recurrent prostate cancer (BCR) is implemented in routine management in many countries and recommended in European Association of Urology (EAU) and American Society of Clinical Oncology (ASCO) guidelines. Purpose of this review is to summarize recently published evidence of accuracy, management impact, and clinical benefit of PSMA PET in this setting and to state our opinion on the role of PSMA PET in future trials and clinical routine to improve patient outcomes. Recent findings The past two years saw an increase of evidence supporting superior detection rates and accuracy of PSMA PET versus standard imaging and other PET radiotracers in the localization of BCR. Systematic reviews, prospective trials and large-scale retrospective studies establish PSMA PET as a new benchmark imaging in this setting and demonstrate considerable impact on therapeutic and diagnostic management. Multiple studies have highlighted pitfalls of PSMA PET imaging warranting attention while interpreting these scans. Summary PSMA PET is the new imaging method of choice in BCR. Recent evidence shows unprecedented accuracy and high detection rates along with translation into management changes in a majority of patients. However, improvement of oncologic outcome has not been assessed yet. Implementation of PSMA PET into clinical trials and management of BCR will be crucial to demonstrate outcome improvement. Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.